Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.60 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ATG7 | O95352 | 10/20 | 0.55 |
| ▸ | DTYMK | P23919 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL766552 | 1.00 | ENPP1 (0.60) | ENPP1P2RY1POLBATG7DTYMK | |
| SCHEMBL16174396 | 1.00 | ENPP1 (0.60) | ENPP1P2RY1POLBATG7DTYMK | |
| SCHEMBL766139 | 0.90 | ATG7 (0.56) | ENPP1P2RY1POLBATG7 | |
| SCHEMBL29390156 | 0.87 | PNP (0.64) | ENPP1P2RY1ATG7 | |
| SCHEMBL22498807 | 0.87 | PNP (0.64) | ENPP1P2RY1ATG7 | |
| SCHEMBL4087758 | 0.85 | RXFP1 (0.66) | P2RY1 | |
| SCHEMBL3904204 | 0.85 | RXFP1 (0.66) | P2RY1 | |
| SCHEMBL13268677 | 0.84 | POLB (0.58) | ENPP1P2RY1POLBATG7DTYMK | |
| SCHEMBL9856198 | 0.83 | ADA (0.47) | ENPP1P2RY1POLB | |
| SCHEMBL6907647 | 0.83 | POLB (0.61) | POLBATG7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100291118-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | INNATE PHARMA (FR) | 2010-11-18 | — | — | US | disclosed |
| US-20100254940-A1 | Compositions and Methods for Regulating an Immune Response in a Subject | INNATE PHARMA, S.A. (FR) | 2010-10-07 | — | — | US | disclosed |
| US-20100222306-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | INNATE PHARMA, S.A. (FR) | 2010-09-02 | — | — | US | disclosed |
| US-7767842-B2 | Class of γδ T cells activators and use thereof | INNATE PHARMA SA (FR) | 2010-08-03 | — | — | US | disclosed |
| US-7683045-B2 | Class of γδ T cells activators and use thereof | INNATE PHARMA S.A. (FR) | 2010-03-23 | — | — | US | disclosed |
| EP-1569656-B1 | PHOSPHOANTIGENS FOR REGULATING AN IMMUNE RESPONSE | INNATE PHARMA (FR) | 2010-03-03 | — | — | EP | disclosed |
| EP-1761278-B1 | ADJUVANT COMPOSITION AND METHODS FOR ITS USE | INNATE PHARMA (FR) | 2008-12-31 | — | — | EP | disclosed |
| US-20080207568-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | INNATE PHARMA S.A. (FR) | 2008-08-28 | — | — | US | disclosed |
| EP-1863572-A2 | NEW CLASS OF T CELLS ACTIVATORS AND USE THEREOF | Innate Pharma (FR) | 2007-12-12 | — | — | EP | disclosed |
| US-20070249565-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | INNATE PHARMA S.A. (FR) | 2007-10-25 | — | — | US | disclosed |
| US-20070218086-A1 | Adjuvant Composition and Methods for Its Use | INNATE PHARMA, S.A. (FR) | 2007-09-20 | — | — | US | disclosed |
| US-20070134273-A1 | Composition and method for the treatment of carcinoma | ROMAGNE FRANCOIS | 2007-06-14 | — | — | US | disclosed |
| EP-1761278-A1 | ADJUVANT COMPOSITION AND METHODS FOR ITS USE | Innate Pharma (FR) | 2007-03-14 | — | — | EP | disclosed |
| EP-1720567-A2 | COMPOSITION AND METHOD FOR THE TREATMENT OF CARCINOMA | Innate Pharma (FR) | 2006-11-15 | — | — | EP | disclosed |
| WO-2006103568-A2 | NEW CLASS OF Ϝδ T CELLS ACTIVATORS AND USE THEREOF | INNATE PHARMA (FR) | 2006-10-05 | — | — | WO | disclosed |
| US-20060194755-A1 | Compositions and methods for regulating an immune response in a subject | INNATE PHARMA, S.A.S. (FR) | 2006-08-31 | — | — | US | disclosed |
| EP-1689758-A2 | NEW CLASS OF GAMMA DELTA T CELLS ACTIVATORS AND USE THEREOF | Innate Pharma (FR) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005102385-A1 | ADJUVANT COMPOSITION AND METHODS FOR ITS USE | INNATE PHARMA (FR) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005077411-A2 | COMPOSITION AND METHOD FOR THE TREATMENT OF CARCINOMA | INNATE PHARMA (FR) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005054258-A2 | NEW CLASS OF GAMMA DELTA T CELLS ACTIVATORS AND USE THEREOF | INNATE PHARMA (FR) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254940-A1 | Compositions and Methods for Regulating an Immune Response in a Subject | IFNG, IL2, ICOS | ENPP1 1076/4885P2RY1 586/4885POLB 2836/4885 |
| US-20080207568-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | NFATC1, CD4, CD74 | ENPP1 1470/4885P2RY1 522/4885POLB 2623/4885 |
| US-20070218086-A1 | Adjuvant Composition and Methods for Its Use | CD4, CD69, ICOS | ENPP1 2055/4885P2RY1 1917/4885POLB 644/4885 |
| US-20070134273-A1 | Composition and method for the treatment of carcinoma | IFNG, IL2, PBK | ENPP1 1323/4885P2RY1 2629/4885POLB 601/4885 |
| US-20100291118-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | CD4, IFNG, NFATC1 | ENPP1 1909/4885P2RY1 900/4885POLB 609/4885 |
| US-20060194755-A1 | Compositions and methods for regulating an immune response in a subject | IFNG, IL2, ICOS | ENPP1 1078/4885P2RY1 588/4885POLB 2656/4885 |
| US-20100222306-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | NFATC1, CD4, CD74 | ENPP1 1470/4885P2RY1 522/4885POLB 2623/4885 |
| US-20070249565-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | CD4, IFNG, NFATC1 | ENPP1 1909/4885P2RY1 900/4885POLB 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.